Table 1.
Baseline characteristics of the study population
| EHD (n=33) | Controls (n=20) | P value | |
|---|---|---|---|
| Demographics | |||
| Age (years) | 57.8±11.0 | 53.7±12.8 | 0.22 |
| Male gender (%) | 17 (51.5) | 12 (60.0) | 0.58 |
| Ethnicity (%) | ND | ND | 0.48 |
| Caucasian | 13 (40.6) | 4 (20.0) | ND |
| African-Canadian | 6 (18.8) | 5 (25.0) | ND |
| Asian | 4 (12.5) | 4 (20.0) | ND |
| Other | 9 (28.1) | 7 (35.0) | ND |
| Cause of ESRD diabetes (%) | 16 (48.5) | 4 (20.0) | 0.046* |
| Baseline access type line (%) | 18 (54.6) | 5 (25.0) | 0.048* |
| Length of dialysis (months) | 19.9 (8.4, 56.1) | 50.8 (24.4, 109.3) | 0.01* |
| Height (cm) | 167.8±11.7 | 164.5±10.5 | 0.33 |
| Weight (kg) | 80.6±21.2 | 69.9±18.4 | 0.09 |
| Body mass index (kg/m2) | 28.4±6.1 | 25.5±5.0 | 0.11 |
| Erythropoietin use (%) | 32 (97.0) | 17 (85.0) | 0.15 |
| Left ventricular mass (g/m2.7) | 136.2±42.2 | 115.6±30.9 | 0.06 |
| Urea reduction ratio (%) | 72±9 | 77±6 | 0.04* |
| Medical History | |||
| Coronary artery disease (%) | 10 (30.3) | 2 (10.0) | 0.10 |
| Cardiovascular disease (%) | 2 (6.1) | 2 (10.0) | 0.63 |
| Cancer (%) | 4 (12.5) | 3 (15.0) | 1.00 |
| Diabetes mellitus (%) | 19 (57.6) | 6 (30.0) | 0.09 |
| Peripheral vascular disease (%) | 5 (15.2) | 3 (15.0) | 1.00 |
| Transplant (%) | 3 (9.1) | 6 (30.0) | 0.07 |
| Medications | |||
| Antiplatelet agents | 20 (54.1) | 19 (63.3) | 0.44 |
| ACE inhibitor/ARB | 27 (73.0) | 22 (73.3) | 0.97 |
| Calcium channel blocker | 18 (48.7) | 6 (20.0) | 0.02 |
| β-Blocker | 18 (48.7) | 17 (56.7) | 0.51 |
| Statin | 19 (51.4) | 12 (40.0) | 0.35 |
| Calcium-containing phosphate binder | 28 (75.7) | 23 (76.7) | 0.92 |
| Sevelamer | 8 (21.6) | 8 (26.7) | 0.63 |
| Biochemical | |||
| Urea reduction ratio (%) | 72±9 | 77±6 | 0.04 |
| Serum albumin (g/L) | 34 (28, 40) | 38 (30, 43) | 0.002* |
| Parathyroid hormone (pmol/L) | 36.1 (19.8, 49.0) | 55.2 (26.7, 95.5) | 0.13 |
| Alkaline phosphatase (U/L) | 87.3 (67.0, 137.0) | 102.5 (65.3, 149.8) | 0.71 |
| Ferritin (ug/L) | 339.0 (218.0, 517.5) | 390.0 (295.0, 815.0) | 0.27 |
| Transferrin saturation | 0.19 (0.16, 0.26) | 0.23 (0.21, 0.26) | 0.28 |
| Hemoglobin A1c (%) | 6 (6, 8) | 6 (5, 7) | 0.06 |
ARB=angiotensin II receptor blocker; ESRD=end stage renal disease; ND=no data obtained.
Table presents subjects’ characteristics as mean±standard deviation or median (quartile 1, quartile 3) or n (%);
*
Significant at P<0.05.